NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study
Open Access
- 19 January 2024
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 95 (9) , 822-828
Abstract
Background: Blood neurofilament light chain (NfL) is increasingly considered as a key trial biomarker in genetic frontotemporal dementia (gFTD). We aimed to facilitate the use of NfL in gFTD multicentre trials by testing its (1) reliability across labs; (2) reliability to stratify gFTD disease stages; (3) comparability between blood matrices and (4) stability across recruiting sites.Methods: Comparative analysis of blood NfL levels in a large gFTD cohort (GENFI) for (1)–(4), with n=344 samples (n=148 presymptomatic, n=11 converter, n=46 symptomatic subjects, with mutations inC9orf72,GRNorMAPT; and n=139 within-family controls), each measured in three different international labs by Simoa HD-1 analyzer.Results: NfL revealed an excellent consistency (intraclass correlation coefficient (ICC) 0.964) and high reliability across the three labs (maximal bias (pg/mL) in Bland-Altman analysis: 1.12±1.20). High concordance of NfL across laboratories was moreover reflected by high areas under the curve for discriminating conversion stage against the (non-converting) presymptomatic stage across all three labs. Serum and plasma NfL were largely comparable (ICC 0.967). The robustness of NfL across 13 recruiting sites was demonstrated by a linear mixed effect model.Conclusions: Our results underline the suitability of blood NfL in gFTD multicentre trials, including cross-lab reliable stratification of the highly trial-relevant conversion stage, matrix comparability and cross-site robustness.Keywords
Funding Information
- Miriam Marks Brain Research UK Senior Fellowship (N/A)
- European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (860197 (MIRIADE))
- Alzheimer Nederland (N/A)
- ZonMw Memorable (733 051 042)
- MRC Clinician Scientist Fellowship (MR/M008525/1)
- National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre (N/A)
- Deutsche Forschungsgemeinschaft German Research Foundation under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy—ID 390857198)
- Bluefield project (N/A)
- Association for Frontotemporal Dementias Research Grant (2009)
- Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831377-C, ADSF-21-831381-C)
- Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862)
- Germany's Federal Ministry of Education and Research (N/A)
- European Reference Network for Rare Neurological Diseases (739510)
- Tau Consortium (N/A)
- Mady Browaeys Fund for Research into Frontotemporal Dementia (N/A)
- National Institute for Health Research Cambridge Biomedical Research Centre (BRC-1215-20014)
- Erling-Persson Family Foundation (N/A)
- Olav Thon Foundation (N/A)
- Medical Research Council (SUAG/051 G101400)
- Ontario Brain Institute (N/A)
- Weston Brain Institute (N/A)
- Dioraphte Foundation (09-02-03-00)
- Canadian Institute of Health Research (327387)
- AD strategic fund (N/A)
- Cambridge University Centre for Frontotemporal Dementia (N/A)
- Brain Foundation (N/A)
- Alzheimer Foundation (N/A)
- Swedish FTD Inititative-Schörling Foundation (N/A)
- Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270)
- European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
- Swedish State Support for Clinical Research (ALFGBG-71320)
- European Union’s Horizon Europe research and innovation programme (101053962)
- Alzheimer’s Research UK Clinical Research Training Fellowship (ARUK-CRF2017B-2)
- Center for Networked Biomedical Research on Neurodegenerative Disease (N/A)
- EU Joint Programme - Neurodegenerative Disease Research Prefrontals (2018-02754, VR 2015-02926, VR Dnr 529-2014-7504)
- Netherlands Organization for Scientific Research (HCMI 056-13-018)
- Swedish Research Council (2019-02397, 2022-01018)
- Else Kröner-Fresenius-Stiftung - Clinician Scientist programme "PRECISE.net" (N/A)
- EU Joint Programme - Neurodegenerative Disease Research GENFI-PROX (2019-02248)
- Italian Ministry of Health (733051042)
- EU Joint Programme - Neurodegenerative Disease Research (N/A)
- Fundación Marat de TV3, Spain (20143810)
- Stockholm County Council ALF (N/A)
- UK Dementia Research Institute at UCL (UKDRI-1003)
- Wellcome Trust (103838)
This publication has 23 references indexed in Scilit:
- Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applicationsJournal of Neurology, Neurosurgery & Psychiatry, 2021
- Likelihood Ratio Approach and Clinical Interpretation of Laboratory TestsFrontiers in Immunology, 2021
- A multi-center study of neurofilament assay reliability and inter-laboratory variabilityAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020
- Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementiaJournal of Neurology, Neurosurgery & Psychiatry, 2020
- Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort studyThe Lancet Neurology, 2019
- The clinical spectrum of sporadic and familial forms of frontotemporal dementiaJournal of Neurochemistry, 2016
- A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability ResearchJournal of Chiropractic Medicine, 2016
- Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysisThe Lancet Neurology, 2015
- An introduction to ROC analysisPattern Recognition Letters, 2006
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986